FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016098890> ?p ?o ?g. }

• W2016098890 endingPage "1342" @default.
• W2016098890 startingPage "1336" @default.
• W2016098890 abstract "Recombinant interleukin (IL)-12 and adenoviral IL-12 gene therapy have been shown to be potent therapeutic interventions for murine transitional cell carcinoma (TCC) of the bladder in vivo. We investigated the mechanisms through which IL-12 induces antibladder cancer immunity.The ability of IL-12 to enhance interferon-gamma (IFN-gamma) expression, a major T-helper type 1 cytokine, was analyzed in murine serum, urine and splenocyte cultures. MB49, a murine TCC line, was treated with IFN-gamma and evaluated for its proliferation, surface molecule expression and sensitivity to splenocyte mediated cytotoxicity. Neutralizing antiIFN-gamma antibody was applied to test the role of IFN-gamma in the IL-12 therapy of MB49 tumor.IL-12 was observed to significantly increase IFN-gamma concentrations in serum and urine as well as in splenocyte cultures. While IL-12 had no direct activity against TCC in vitro, IFN-gamma showed potent dose dependent antiproliferative and pro-apoptotic activity, which was further enhanced by supplementation of tumor necrosis factor-alpha. In addition, IFN-gamma substantially up-regulated the expression of surface immune molecules on TCC cells, including MHC-I, MHC-II, ICAM-I, B7.1, B7.2 and Fas. Maximum splenocyte mediated cytotoxicity against TCC was enhanced by pretreatment of target bladder cancer cells with IFN-gamma plus tumor necrosis factor-alpha. Furthermore, IL-2 in combination with IL-12 further enhanced splenocyte mediated cytotoxicity. The in vivo antibladder cancer activity of IL-12 was abolished by concurrent treatment with antibodies to IFN-gamma.This study strongly suggests that IFN-gamma has an essential role in IL-12 induced antibladder tumor immunity. Activation of host effector immune cells by IL-12 is also required for induction of optimal tumor destruction in IL-12 therapy." @default.
• W2016098890 created "2016-06-24" @default.
• W2016098890 creator A5003263712 @default.
• W2016098890 creator A5013392249 @default.
• W2016098890 creator A5024525935 @default.
• W2016098890 creator A5065220600 @default.
• W2016098890 creator A5074299401 @default.
• W2016098890 creator A5076731661 @default.
• W2016098890 date "2004-03-01" @default.
• W2016098890 modified "2023-09-26" @default.
• W2016098890 title "The Essential Role of Interferon-γ During Interleukin-12 Therapy for Murine Transitional Cell Carcinoma of the Bladder" @default.
• W2016098890 cites W1607695063 @default.
• W2016098890 cites W1967178789 @default.
• W2016098890 cites W1976899534 @default.
• W2016098890 cites W1985029921 @default.
• W2016098890 cites W1991464867 @default.
• W2016098890 cites W1993051112 @default.
• W2016098890 cites W1996062441 @default.
• W2016098890 cites W2005516149 @default.
• W2016098890 cites W2026318599 @default.
• W2016098890 cites W2028688116 @default.
• W2016098890 cites W2038260086 @default.
• W2016098890 cites W2046399828 @default.
• W2016098890 cites W2071737533 @default.
• W2016098890 cites W4250497858 @default.
• W2016098890 cites W4313335045 @default.
• W2016098890 doi "https://doi.org/10.1097/01.ju.0000109751.60921.da" @default.
• W2016098890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14767344" @default.
• W2016098890 hasPublicationYear "2004" @default.
• W2016098890 type Work @default.
• W2016098890 sameAs 2016098890 @default.
• W2016098890 citedByCount "16" @default.
• W2016098890 countsByYear W20160988902012 @default.
• W2016098890 countsByYear W20160988902013 @default.
• W2016098890 countsByYear W20160988902015 @default.
• W2016098890 countsByYear W20160988902016 @default.
• W2016098890 countsByYear W20160988902019 @default.
• W2016098890 countsByYear W20160988902021 @default.
• W2016098890 countsByYear W20160988902022 @default.
• W2016098890 crossrefType "journal-article" @default.
• W2016098890 hasAuthorship W2016098890A5003263712 @default.
• W2016098890 hasAuthorship W2016098890A5013392249 @default.
• W2016098890 hasAuthorship W2016098890A5024525935 @default.
• W2016098890 hasAuthorship W2016098890A5065220600 @default.
• W2016098890 hasAuthorship W2016098890A5074299401 @default.
• W2016098890 hasAuthorship W2016098890A5076731661 @default.
• W2016098890 hasConcept C109316439 @default.
• W2016098890 hasConcept C121608353 @default.
• W2016098890 hasConcept C126322002 @default.
• W2016098890 hasConcept C150903083 @default.
• W2016098890 hasConcept C17991360 @default.
• W2016098890 hasConcept C189976730 @default.
• W2016098890 hasConcept C202751555 @default.
• W2016098890 hasConcept C203014093 @default.
• W2016098890 hasConcept C207001950 @default.
• W2016098890 hasConcept C2777371288 @default.
• W2016098890 hasConcept C2778690821 @default.
• W2016098890 hasConcept C2780352672 @default.
• W2016098890 hasConcept C2780841837 @default.
• W2016098890 hasConcept C502942594 @default.
• W2016098890 hasConcept C55493867 @default.
• W2016098890 hasConcept C71924100 @default.
• W2016098890 hasConcept C86803240 @default.
• W2016098890 hasConcept C8891405 @default.
• W2016098890 hasConceptScore W2016098890C109316439 @default.
• W2016098890 hasConceptScore W2016098890C121608353 @default.
• W2016098890 hasConceptScore W2016098890C126322002 @default.
• W2016098890 hasConceptScore W2016098890C150903083 @default.
• W2016098890 hasConceptScore W2016098890C17991360 @default.
• W2016098890 hasConceptScore W2016098890C189976730 @default.
• W2016098890 hasConceptScore W2016098890C202751555 @default.
• W2016098890 hasConceptScore W2016098890C203014093 @default.
• W2016098890 hasConceptScore W2016098890C207001950 @default.
• W2016098890 hasConceptScore W2016098890C2777371288 @default.
• W2016098890 hasConceptScore W2016098890C2778690821 @default.
• W2016098890 hasConceptScore W2016098890C2780352672 @default.
• W2016098890 hasConceptScore W2016098890C2780841837 @default.
• W2016098890 hasConceptScore W2016098890C502942594 @default.
• W2016098890 hasConceptScore W2016098890C55493867 @default.
• W2016098890 hasConceptScore W2016098890C71924100 @default.
• W2016098890 hasConceptScore W2016098890C86803240 @default.
• W2016098890 hasConceptScore W2016098890C8891405 @default.
• W2016098890 hasIssue "3" @default.
• W2016098890 hasLocation W20160988901 @default.
• W2016098890 hasLocation W20160988902 @default.
• W2016098890 hasOpenAccess W2016098890 @default.
• W2016098890 hasPrimaryLocation W20160988901 @default.
• W2016098890 hasRelatedWork W1493607500 @default.
• W2016098890 hasRelatedWork W1968030834 @default.
• W2016098890 hasRelatedWork W1970372326 @default.
• W2016098890 hasRelatedWork W1994050787 @default.
• W2016098890 hasRelatedWork W2038313892 @default.
• W2016098890 hasRelatedWork W2070650056 @default.
• W2016098890 hasRelatedWork W2092231216 @default.
• W2016098890 hasRelatedWork W2120080131 @default.
• W2016098890 hasRelatedWork W2271232808 @default.
• W2016098890 hasRelatedWork W2954491084 @default.
• W2016098890 hasVolume "171" @default.

• next